Brief: Marker Therapeutics Reports Fiscal Year 2022 Corporate And Financial Results
22/03/2023 12:11
March 22 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS FISCAL YEAR 2022 CORPORATE AND
FINANCIAL RESULTS
* MARKER THERAPEUTICS - BELIEVES EXISTING CASH, EQUIVALENTS,
RESTRICTED CASH TO FUND OPERATING EXPENSES, CAPITAL EXPENDITURE
REQUIREMENTS INTO Q3 2023
Source text for Eikon: ID:nGNXbRn9rL
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79